Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.18, moving -3.34% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.57%.

Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on ...

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, ...

Robots and AI are running experiments around the clock, from battery chemistry to cancer therapies. But can they be trusted ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enliven Therapeutics (ELVN) and Twist Bioscience (TWST) with bullish sentiments. Unlock powerful ...

D-Wave Quantum saw its share prices climb by 12.37 percent on Monday to close at $26.26 apiece, mirroring a wider market ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...

Small-cap biotech names are gaining attention as clinical readouts and medical conference updates shape market sentiment ...

A tiny set of ancient genetic “switches” may have played a surprisingly large role in making human language possible.

Civic virtue, domestic violence and Raymond Berry, in readers’ eyes.